

# TABLE OF CONTENTS

April 13, 2009

No. 2135

## BUSINESS

- 1 Bayer to Pursue Growth Rate Twice as High as Industry Average  
- Japan Continues to Be an Attractive Market  
- Helping Female MRs Continue to Work  
- iPS Cells Out of Focus  
- Bayer HealthCare, Genzyme Enter Strategic Agreement

- 3 Takeda Further Globalizes Its Business Structure  
- Creating Marketing Company in Canada  
- Expanding Own Sales and Marketing Operations in Europe

- 4 Chugai Will Remain Independent Despite Acquisition of Genentech by Roche

- 4 MediciNova to Suspend All Negotiations on MN-166 for MS

- 5 Taiho Licenses Yondelis from PharmaMar

- 5 Eisai Licenses Urief from Kissei in ASEAN Countries, India

- 5 Mochida Aims at ¥84.5 Bil. Sales in FY2011

- 6 Co-DIO, Ecard Jump to 1st and 2nd Place on GP Market: Rep Track Survey

## NEW PRODUCTS

- Toray, JT, Torii: Remitch to Control Itching in Hemodialysis Patients  
- Bayer HealthCare: Fosrenol to Treat Hyperphosphatemia

## BUSINESS NEWS IN BRIEF

- MTPC Licenses Dementia Treatment from EnVivo  
- Tella Obtains License for New Cancer Antigen  
- Nitten Obtains License for AzaSite from InSite Vision  
- Quintiles Completes World's Largest CAP-Accredited Central Lab Network  
- Ranbaxy Launches Olmesartan in India

## GENERICS

- 9 Actavis ASKA Aims at Sales of ¥10 Bil. by 2015  
9 22 Companies to Apply for NHI Price Listing for Generics of Cravit

- 10 Pharmacists Hold Key to Promotion of the Use of Generics: Mr Isobe  
- Pharmacists Are Not Cooperative  
- Efficacy, Safety of Generic Amlodipine Confirmed through Clinical Study

- 11 Hansha's Sales Forces May Help Generics Makers Provide Information

## GENERICS NEWS IN BRIEF

- Mylan Seiyaku Kicks Off Cancer-Specialized Team

## TOPICS

- 10 - Society of Applied Therapeutics to Be Inaugurated

## R&D

- 12 Daiichi Sankyo to Apply for DU-176b as Japan's First Oral Anti-Xa Agent  
- Prasugrel to Be Approved within April in US

- 12 Daiichi Sankyo Reshuffles R&D Structures to Quickly Develop Biologics

- 13 InCROM Clinical Research Unit Certified by MHRA

## R&D NEWS IN BRIEF

- Enrollment Completed in Japan for PREDICTIVE Study on Levemir: Novo Nordisk  
- Medinet Begins Clinical Research Program for Malignant Glioma

## REGULATORY

- 14 FDA's Advisory Committee Recommends Approval for ONGLYZA

- 15 Celgene to File an NDA for Lenalidomide in 2010

## REGULATORY NEWS IN BRIEF

- Takeda Applies for Combination of Blopres + Amlodipine  
- Takepron Applied for to Prevent Aspirin-Induced Ulcers  
- Alexion Applies for Eculizumab  
- Daiichi Sankyo to Deal Directly with FDA to Solve Problems with Data from Ranbaxy  
- Everolimus Approved in US

## SELF-MEDICATION

- 16 Points of Discussion on Online Sale of Drugs Listed

- 17 Daiichi Sankyo to Place Top Priority on Class-1 Products

## NEW PRODUCTS

- Taisho to Launch Switch OTC Containing Diclofenac  
- OTC Version of Voltaren Approved: Novartis

## TOPICS

- 17 - JKMA Publishes English Terminology for Kampo Medicines

## MEDICAL DEVICES

- 18 Council to Focus on Differences in Prices of Medical Devices in Japan and Abroad

## MEDICAL DEVICE NEWS IN BRIEF

- Medtronic Japan Launches Endeavor Coronary Stent System  
- FUJIREBIO Launches ESPLINE HIV Ag/Ab for Quick HIV Detection

## MEDICAL FACILITIES & NURSING CARE

- 20 JCS (Japanese Circulation Society) 2009  
- Japanese-Unique Factor Identified in PII Trial of DU-176b

- Early Identification of Relevant Ethnic Factors Important

- 21 Lucentis to Become the Mainstay for AMD in Japan as Well

- 22 Optimal Antiviral Therapy Important to Prevent Liver Cancer: Dr Izumi

- 22 Synergistic Effects Can Be Expected with Adoair  
23 UFT as Effective as CMF for Postoperative Breast Cancer

## New Book

- Supportive Care Perspectives 2008 (SCP2008) from Synix